The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease
NCT ID: NCT00090116
Last Updated: 2012-03-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
400 participants
INTERVENTIONAL
2003-03-31
2005-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease
NCT00322153
Nefiracetam in the Treatment of Alzheimer's Disease
NCT00001933
An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease
NCT00097916
Memantine Versus Donepezil in Early Stages of Alzheimer's Disease
NCT00505167
Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease
NCT00933608
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Neramexane
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ambulatory patients
Exclusion Criteria
* clinically significant central nervous system disease other than Alzheimer's disease;
* clinically significant pulmonary, gastrointestinal, renal, hepatic, endocrine or cardiovascular disease
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Forest Laboratories
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pivotal Research Centers
Peoria, Arizona, United States
21st Century Neurology
Phoenix, Arizona, United States
Margolin Brain Institute
Fresno, California, United States
Pharmacology Research Institute
Northridge, California, United States
UCI Medical Center
Orange, California, United States
Pacific Research Network
San Diego, California, United States
Affiliated Research Institute
San Diego, California, United States
University of Colorado Health Sciences Center
Denver, Colorado, United States
Yale University School of Medicine
New Haven, Connecticut, United States
Baumel-Eisner Neuromedical Institute
Fort Lauderdale, Florida, United States
Berma Research Group
Hialeah, Florida, United States
Palm Beach Neurological Center
Palm Beach Gardens, Florida, United States
Neurology Clinical Research, Inc.
Plantation, Florida, United States
University of South Florida
Tampa, Florida, United States
Palm Beach Neurology
West Palm Beach, Florida, United States
Indiana Universisty Medical Center
Indianapolis, Indiana, United States
Lexington Clinic
Lexington, Kentucky, United States
J. Gary Booker, MD
Shreveport, Louisiana, United States
Mood and Memory Clinic of Michigan
Farmington Hills, Michigan, United States
St. Louis University
St Louis, Missouri, United States
Alzheimer's Research Corporation
Lakehurst, New Jersey, United States
Joel Ross, MD
Long Branch, New Jersey, United States
Ubhc/Umdnj
Piscataway, New Jersey, United States
Upstate Clinical Research
Albany, New York, United States
Nathan S. Kline Institute for Psychiatric Research
Orangeburg, New York, United States
Monroe Community Hospital
Rochester, New York, United States
Behavioral Medical Research of Saten Island, PC
Staten Island, New York, United States
Piedmont Medical Research
Winston-Salem, North Carolina, United States
Ohio State University
Columbus, Ohio, United States
Neurology and Neuroscience Center of Ohio
Toledo, Ohio, United States
Summit Research Network
Portland, Oregon, United States
Medical University of South Carolina
Charleston, South Carolina, United States
North Texas Neurology Research
Wichita, Texas, United States
Pioneer Pharmaceutical Research
Midvale, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NER-MD-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.